Evidence map›Paper›PMID 40456777›Full record

ArticleNature communications2025

ELMO2 is an essential regulator of carotid artery development.

Athira Suresh, Kai Kruse, Hendrik Arf, Rodrigo Diéguez-Hurtado, Ralf H Adams

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Targeting of ELMO2 by thebioRxiv : the preprint server for biology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Athira SureshMax Planck Institute for Molecular Biomedicine, Department of Tissue Morphogenesis, Münster, Germany.ORCID http://orcid.org/0009-0002-3776-8374
Kai KruseMax Planck Institute for Molecular Biomedicine, Bioinformatics Service Unit, Münster, Germany.ORCID http://orcid.org/0000-0002-7951-7357
Hendrik ArfMax Planck Institute for Molecular Biomedicine, Department of Tissue Morphogenesis, Münster, Germany.ORCID http://orcid.org/0000-0002-2038-705X
Rodrigo Diéguez-HurtadoMax Planck Institute for Molecular Biomedicine, Department of Tissue Morphogenesis, Münster, Germany. rodrigo.hurtado@mpi-muenster.mpg.de.ORCID http://orcid.org/0000-0002-2055-599X
Ralf H AdamsMax Planck Institute for Molecular Biomedicine, Department of Tissue Morphogenesis, Münster, Germany. ralf.adams@mpi-muenster.mpg.de.ORCID http://orcid.org/0000-0003-3031-7677

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 394046768EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) AdG 101139772
6 · The paper itself

Abstract

Engulfment and cell motility 2 (ELMO2) is a cytoskeletal adaptor protein necessary for cell migration and apoptotic cell removal. Loss-of-function mutations in ELMO2 cause intraosseous vascular malformation (VMOS), a human disease involving progressive expansion of craniofacial bones in combination with anomalies in blood vessels that emerge from the external carotid artery, as well as aneurysms in the internal carotid artery. Here we show that global inactivation of Elmo2 in mice leads to midgestation embryonic lethality due to dilation of the 3

Indexed as

Adaptor Proteins, Signal TransducingCarotid ArteriesActinsAnimalsCell AdhesionCell MovementFemaleHumansMaleMiceMice, Inbred C57BLMice, KnockoutMuscle, Smooth, VascularMyocytes, Smooth MuscleNeural CrestNeuropeptidesActinsAdaptor Proteins, Signal TransducingNeuropeptidesrac1 GTP-Binding ProteinRac1 protein, mouse

Identifiers

PMID40456777
PMCPMC12130350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.